KR102380735B1 - Peptides able to neutralize severe acute respiratory syndrome coronavirus 2 - Google Patents

Abstract

The present invention relates to a peptide that specifically recognizes a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus (SARS-CoV-2), wherein the peptide of the present invention is SARS-CoV -2 It has an excellent binding ability to the spike protein on the surface and is very useful for preventing, treating or diagnosing SARS-CoV-2 infection.

Description

Peptides able to neutralize severe acute respiratory syndrome coronavirus 2 having neutralizing activity against type 2 severe acute respiratory syndrome coronavirus

The present invention relates to a peptide having neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) of type 2 and uses thereof.

Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is a single-stranded RNA (RNA) virus belonging to the subfamily of coronaviruses, and the cause of the outbreak in Wuhan, China in December 2019 The causative virus was first discovered in a patient with unknown pneumonia. Not to be confused with Severe Acute Respiratory Syndrome Infectious Disease, the World Health Organization (WHO) also calls it the '2019 coronavirus infection virus' or '2019 coronavirus infectious disease responsible virus'.

From December 2019 to early July 2020, there were 11.57 million confirmed cases in 214 countries around the world, of which 537,138 died, resulting in a fatality rate of 4.64. The clinical symptoms of SARS-CoV-2 are mainly respiratory symptoms accompanied by fever. Unlike previous viruses, the WHO declared a global pandemic, a pandemic, in March 2020, less than three months after the initial report, showing strong contagiousness and rapid worsening of symptoms.

There is no specific treatment yet, but research on antiviral drugs has progressed, and research on antiviral drugs has been conducted, so it is possible to use the RNA polymerase inhibitor remdesivir, the malaria drug chloroquine, and the antiretroviral human immunodeficiency I protease inhibitor lopinavir/ritonavir. It has been reported that antiviral agents exhibit SARS-CoV-2 inhibitory effects at the cellular level. However, therapeutic agents that are known to be effective so far have become a problem because their effectiveness is insignificant or may cause various side effects in actual clinical practice.

Accordingly, the present inventors have made intensive efforts to develop a new therapeutic agent capable of inhibiting SARS-CoV-2. As a result, the present invention confirmed that the peptides of the present invention can be usefully used for the prevention, improvement or treatment of coronavirus infection. completed.

One object of the present invention is to provide a peptide that specifically recognizes a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus (SARS-CoV-2).

Another object of the present invention is to provide a composition for preventing or treating SARS-CoV-2 infection comprising the peptide.

Another object of the present invention is to provide a composition for diagnosis of SARS-CoV-2 comprising the peptide.

To this end, one aspect of the present invention provides a peptide that specifically recognizes a protein of type 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a part thereof.

In addition, another aspect of the present invention provides a composition for preventing or treating SARS-CoV-2 infection comprising the peptide.

In addition, another aspect of the present invention provides a composition for diagnosis of SARS-CoV-2 comprising the peptide.

The peptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 6 of the present invention binds to the spike protein on the surface of SARS-CoV-2 to neutralize SARS-CoV-2, thereby causing viruses and host cells Since it has an effect of inhibiting membrane fusion of the SARS-CoV-2 infection, it can be used for prevention, treatment or diagnosis.

However, the effects of the present invention are not limited to the above-mentioned effects, and other effects not mentioned will be clearly understood by those skilled in the art from the following description.

1 is a graph showing the results of confirming the ability of the peptides of SEQ ID NOs: 1 to 6 of the present invention to bind to the RBD of the SARS-CoV-2 spike protein by ELISA.
Figure 2 is an ELISA activity of the peptides of SEQ ID NOs: 1 to 6 of the present invention inhibiting the binding of the RBD of the SARS-CoV-2 spike protein to the angiotensin-converting enzyme 2 (ACE2) protein of the host cell. It is a graph showing the confirmed result.
3 shows the results of confirming by Western blot whether the peptides of SEQ ID NOs: 1 to 4 of the present invention have the ability to inhibit the binding of RBD to ACE2 expressed on the cell surface of the human lung cancer cell line A549.

Hereinafter, the present invention will be described in detail.

One aspect of the present invention specifically recognizes a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the sequence of SEQ ID NOs: 1 to 6 It provides a peptide comprising any one amino acid sequence selected from the group consisting of.

As used herein, the term 'peptide' refers to a linear or cyclic molecule formed by combining amino acid residues with each other by peptide bonds. The production of the peptide may be accomplished by a conventional biological or chemical synthesis method known in the art, and for example, it may be achieved by a method such as solid-phase synthesis techniques.

The 'peptide' may be variants or fragments of amino acids having different sequences by deletion, insertion, substitution, or a combination of amino acid residues within the range that does not affect the function. Amino acid exchanges that do not entirely alter the activity of the peptide are known in the art. In some cases, it may be transformed into phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, and the like. Accordingly, the present invention includes peptides having substantially the same amino acid sequence as a peptide comprising any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 6, and variants or active fragments thereof. The substantially identical protein is 75% or more, preferably 80% or more, such as 85% or more, 90% or more, 95% or more, 98% or more of any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 6 It means an amino acid sequence having % or more, or 99% or more sequence homology, but is not limited thereto. In addition, the peptide of the present invention may additionally include a targeting sequence, a tag, a labeled residue, an amino acid sequence prepared for a specific purpose to increase the half-life or peptide stability.

In addition, in order to obtain better chemical stability, enhanced pharmacological properties (half-life, absorption, potency, potency, etc.), altered specificity (e.g., broad spectrum of biological activity), reduced antigenicity, the N of the peptides of the present invention A protecting group may be attached to the -terminus or C-terminus. For example, the protecting group may be an acetyl group, a fluorenyl methoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, or polyethylene glycol (PEG). If there is an ingredient, it may be included without limitation. The 'stability' is used to include not only stability in vivo, which protects the peptide of the present invention from attack by in vivo protein cleavage enzymes, but also storage stability (eg, storage stability at room temperature).

In one embodiment, the peptide of the invention is selected from the group consisting of:

RSYMTTHHEQF (SEQ ID NO: 1);

KFNRHH (SEQ ID NO: 2);

KYLLVHRPYYRR (SEQ ID NO: 3);

WVPYQARVPYPR (SEQ ID NO: 4);

RLYCKNGGFFLR (SEQ ID NO: 5); and

KHRGGGNRR (SEQ ID NO: 6).

The peptide of the present invention can specifically bind to the spike protein (S protein) of SARS-CoV-2. More specifically, the peptide of the present invention can specifically bind to a receptor binding domain (RBD) present in the spike protein of SARS-CoV-2.

As used herein, the term “specifically binds” means that it binds to a protein of interest, that is, the spike protein of SARS-CoV-2 or RBD, which is a part thereof, but does not substantially recognize and bind other molecules in the sample.

The peptide of the present invention can inhibit the binding of the spike protein to the cell membrane receptor of the host cell by specifically binding to the spike protein on the surface of SARS-CoV-2.

The cell membrane receptor of the host cell is angiotensin-converting enzyme 2 (ACE2), and angiotensin-converting enzyme 2 is a transmembrane protein found in eukaryotes and bacteria. It is a receptor used to invade

In one embodiment, the peptide of the present invention can neutralize SARS-CoV-2 by specifically binding to the spike protein RBD on the surface of SARS-CoV-2, and SARS-CoV-2 binds to the cell membrane of the host cell. It was confirmed that it can inhibit

As used herein, the term “neutralization” refers to the ability to inhibit SARS-CoV-2 replication in vivo and/or in vitro, regardless of the mechanism by which neutralization is achieved. In one embodiment, the peptide of the present invention neutralizes SARS-CoV-2 by inhibiting SARS-CoV-2 adhesion to a target cell and fusion of the viral membrane with the cell membrane.

Another aspect of the present invention provides a pharmaceutical composition for preventing or treating type 2 severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection comprising the peptide.

The composition can prevent or treat SARS-CoV-2 infection by binding to the spike protein on the surface of the type 2 severe acute respiratory syndrome coronavirus and inhibiting the binding of the spike protein to the cell membrane receptor of the host cell.

The pharmaceutical composition for the prevention or treatment of SARS-CoV-2 infection of the present invention can be prepared according to a conventional method for oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, And it may be formulated and used in the form of a sterile injection solution, and may further include a pharmaceutically acceptable carrier, excipient or diluent in addition to the peptide for formulation.

The pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl, which are commonly used in formulation. pyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.

The pharmaceutical composition may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.

The pharmaceutical composition may be administered orally or parenterally (eg, intramuscularly, intravenously, intraperitoneally, subcutaneously, intradermally, or locally applied) according to a desired method, and the dosage may vary depending on the patient's condition and Although it varies depending on body weight, disease severity, drug form, administration route and time, it may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, a 'pharmaceutically effective amount' means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity, and drug activity of the patient; Sensitivity to the drug, administration time, administration route and excretion rate, treatment period, factors including concurrent drugs and other factors well known in the medical field may be determined. The pharmaceutical composition may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, may be administered simultaneously with, separately, or sequentially from a conventional therapeutic agent, and may be administered single or multiple. Taking all of the above factors into consideration, it is important to administer an amount capable of obtaining the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.

The effective amount of the pharmaceutical composition may vary depending on the patient's age, sex, condition, weight, absorption of the active ingredient into the body, inactivation rate, excretion rate, disease type, and drugs used in combination, the route of administration, the severity of obesity, It may be increased or decreased according to gender, weight, age, etc., for example, the pharmaceutical composition may be administered per 1 kg of the patient's body weight per day, about 0.0001㎍ to 500mg, preferably 0.01㎍ to 100mg.

The pharmaceutical composition of the present invention may further comprise at least one other therapeutic agent. For example, interferon, anti-S protein monoclonal antibody, anti-S protein polyclonal antibody, nucleoside analog, DNA polymerase inhibitor, siRNA agent or therapeutic vaccine as an antiviral drug, along with the peptide may include These can be used in combination with the peptides of the present invention. As used herein, “in combination” means following administration as separate formulations or as one single combination formulation simultaneously, or sequentially in any order, as separate formulations.

In another aspect, the present invention provides a composition for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprising the peptide.

The composition for detecting SARS-CoV-2 of the present invention can be used to detect the presence or absence of SARS-CoV-2 in a biological sample by confirming a reaction after contacting the biological sample with the peptide.

The peptides of the present invention may be detectably labeled. Examples of labels that can be used in the present invention include enzymes, radioactive isotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds and bioluminescent compounds. Commonly used labels include fluorescent substances (eg, fluorescein, rhodamine, Texas red, etc.), enzymes (eg, horseradish peroxidase, β-galactosidase, alkaline phosphatase), radioactive isotopes (eg, 32P or 125I), biotin, digoxigenin, colloidal metals, chemiluminescent or bioluminescent compounds (eg, dioxetane, luminol or acridinium). Labeling methods such as covalent bonding of enzymes or biotinyl groups, iodination, phosphorylation, and biotinylation are well known in the art.

The detection of the presence of SARS-CoV-2 is performed by enzyme immunoassay (ELISA), Western blotting, immunofluorescence, immunohistochemistry staining, flow cytometry, and immune cells. By any one selected from the group consisting of chemical method, radioimmunoassay (RIA), immunoprecipitation assay, immunodiffusion assay, complement fixation assay, and protein chip can be carried out.

The enzyme immunosorbent method (ELISA) includes a direct ELISA using a labeled antibody recognizing a peptide attached to a solid support, and an indirect ELISA using a labeled secondary antibody recognizing a capture antibody in a complex of an antibody recognizing a peptide attached to a solid support. It includes various ELISA methods such as ELISA.

The biological sample may be any one selected from the group consisting of sputum, saliva, blood, sweat, respiratory tissue, and saliva of the subject, but is not limited thereto, and the sample may be prepared by a conventional method known in the art.

The present invention also provides a kit for diagnosing SARS-CoV-2 infection or disease comprising the peptide.

As used herein, the term “SARS-CoV-2 infection or disease” refers to a pathological condition resulting from infection of a cell or a subject by SARS-CoV-2, for example, the disease is caused by SARS-CoV-2 It may be caused by respiratory disease.

In the diagnostic kit of the present invention, the kit may include a solid carrier. The peptides of the invention may be attached to a solid carrier, which may be porous or non-porous, planar or non-planar.

Hereinafter, the present invention will be described in detail by way of Examples and Experimental Examples.

However, the following Examples and Experimental Examples are only for illustrating the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

Selection of peptides of the present invention

In order to develop a peptide that inhibits the binding of SARS-CoV-2 spike protein (S protein) and angiotensin-converting enzyme 2 (ACE2), six types of peptides were screened from the peptide library. was selected. The sequence of the selected peptide and the molecular weight of the peptide measured using a molecular weight analyzer are shown in Table 1 below.

NO amino acid sequence Molecular Weight (Da) SEQ ID NO: One RSYMTTHHEQF 1437 One 2 KFNRRHH 994.1 2 3 KYLLVHRPYYRR 1664 3 4 WVPYQARVPYPR 1532 4 5 RLYCKNGGFFLR 1474 5 6 KHRGGGNRR 1037 6

Confirmation of binding ability of the peptide of the present invention to SARS-CoV-2 spike protein RBD

In order to check whether the peptides of the present invention can block the invasion of host cells of SARS-CoV-2, it was first confirmed whether the peptides of the present invention could recognize and bind to the RBD in the SARS-CoV-2 spike protein.

Specifically, the 6 types of peptides selected in Experimental Example 1 were mixed with 2 mM sodium bicarbonate in the same volume, dispensed in a 96-well plate at 100 μL, and then incubated at 4° C. overnight to coat the well surface with the peptide. . After washing 3 times with 0.1% PBS-T (0.1% Tween-20 in PBS), 100 μL of 3% BSA was dispensed, blocked at room temperature for 1 hour, and washed 3 times with 0.1% PBS-T. Thereafter, 100 ng of recombinant SARS-CoV-2 spike RBD-His (Sino Biological, Cat. No.: 40592-V08B, China) was treated per well and reacted at room temperature for 2 hours. After washing 3 times with 0.1% PBS-T, anti-His antibody-HRP (Abcam, Cat. No.: ab1187, US) was diluted 1:1000 in PBS and reacted for 1 hour at room temperature, followed by 0.1% PBS -T washed 3 times. 100 μL of TMB solution (ThermoFisher, Cat. No.: N301, US) was dispensed and reacted for about 5 minutes, followed by treatment with 50 μL of 1M sulfuric acid to terminate the reaction. O.D. at a wavelength of 450 nm using a spectrometer. The values were measured.

As a result, as shown in [Fig. 1], when the binding pattern to RBD of each of the peptides of SEQ ID NOs: 1 to 6 was observed by ELISA, it was confirmed that the binding fold to RBD increased in a concentration-dependent manner of the peptide. .

Through this, it can be seen that the peptide of the present invention has the ability to recognize and bind to the RBD of the SARS-CoV-2 spike protein.

Confirmation of ACE2-RBD binding inhibitory ability of the peptide of the present invention

In order to confirm whether the peptides of the present invention can block the invasion of the host cell by SARS-CoV-2, it was confirmed whether the peptides of the present invention inhibit the binding of ACE2, a membrane protein of the host cell, to the RBD of SARS-CoV-2.

Specifically, 2mM sodium bicarbonate and ACE2-FC protein (Sino Biological, Cat. No.: 10108-H02H, China) were mixed in the same volume, and 100ng/100 μL/well was dispensed in a 96-well plate, then 4 The well surface was coated with ACE2 protein by overnight incubation at °C. After washing 3 times with 0.1% PBS-T (0.1% Tween-20 in PBS), 100 μL of 3% BSA was dispensed, followed by blocking at room temperature for 1 hour. 100 ng of recombinant SARS-CoV-2 spike RBD His (Sino Biological, Cat. No.: 40592-V08B, China) in PBS and a peptide solution for each concentration were mixed and reacted at room temperature for 1 hour. The wells were washed 3 times with 0.1% PBS-T, and then the protein-peptide mixture was applied to the wells. After reacting at room temperature for 2 hours, it was washed 3 times with 0.1% PBS-T. Anti-His antibody-HRP (Abcam, Cat. No.: ab1187, US) was diluted 1:1000 in PBS and reacted for 1 hour at room temperature, followed by washing 3 times with 0.1% PBS-T. 100 μL of TMB solution (ThermoFisher, Cat. No.: N301, US) was dispensed and reacted for about 5 minutes, followed by treatment with 50 μL of 1M sulfuric acid to terminate the reaction. O.D. at a wavelength of 450 nm using a spectrometer. The values were measured.

As a result, as shown in [Fig. 2], it was confirmed that each of the peptides of SEQ ID NOs: 1 to 6 inhibited the binding of RBD to the ACE2 protein in a concentration-dependent manner.

Through this, it can be seen that the peptide of the present invention binds to the RBD of the spike protein of SARS-CoV-2, thereby inhibiting the binding of the spike protein to the ACE2 protein.

Confirmation of ACE2-RBD binding inhibitory ability of the peptide of the present invention in human lung cancer cells

In order to confirm whether the peptide of the present invention has the ability to prevent, improve, and treat coronavirus infection in mammalian cells, the binding ability of the SARS-CoV-2 spike protein RBD to ACE2 of host cells after treatment with the peptides in human lung cancer cell lines was confirmed to decrease.

Specifically, A549 cells (Korean Cell Line Bank, Cat.No.: 10185, Korea), which are adenocarcinomic human alveolar basal epithelial cells, were inoculated into a 6-well plate at a density of 5x10 ⁵ cells/well and inoculated for 24 hours. cultured. 500 ng of recombinant SARS-CoV-2 spike RBD His (Sino Biological, Cat. No.: 40592-V08B, China) was mixed in 1 mL of DMEM medium and a peptide solution for each concentration was mixed and reacted at room temperature for 1 hour. A549 cells cultured for one day were washed with DMEM medium, and then 900 μL of recombinant SARS-CoV-2 spike RBD/peptide mixture was added to the cells. After culturing for 2 hours in a CO ₂ incubator at 37° C., the cells were washed twice with PBS and treated with 200 μL of lysis buffer to lyse the cells. After preparing a sample by processing 5X sample buffer, SDS-PAGE was performed using a 10% SDS-PAGE gel. Proteins separated by SDS-PAGE were transferred to a PVDF membrane, and then blocked using 5% skim milk at room temperature for 1 hour. Next, anti-His antibody-HRP (Abcam, Cat. No.: ab1187, US) was diluted 1:1000 in 5% skim milk, reacted with the membrane for 2 hours, and 0.1% PBS-T (0.1% Tween- 20 in PBS) was washed 3 times for 10 minutes each. Film detection was performed using an ECL solution (GE Healthcare, Cat. No.: RPN2232, US).

As a result, as shown in [Fig. 3], it was confirmed that each of the peptides of SEQ ID NOs: 1 to 4 of the present invention inhibited the binding of ACE2 and SARS-CoV-2 spike RBD in host cells in a concentration-dependent manner.

Through this, it can be seen that the peptide of the present invention binds to the spike protein of SARS-CoV-2 and inhibits the binding of the spike protein to ACE2 of the host cell, thereby preventing or treating virus infection in the host cell. .

Confirmation of the inhibitory effect of the peptide of the present invention on SARS-CoV-2 cell infection

Focus Reduction Neutralizing Test (FRNT) was performed to directly confirm whether the peptide of the present invention has an effect of inhibiting cell infection by SARS-CoV-2.

Specifically, Vero E6 cells (ATCC, USA) were inoculated in a 96-well plate at a density of 2X10 ⁴ cells/well, and then cultured to 90-100% confluency. 500 focus-forming units (FFU)/well of SARS-CoV-2 and peptide samples by concentration were mixed 1:1 and reacted at 37°C for 1 hour. The peptide and virus mixture was treated on Vero E6 cell monolayer and incubated at 37 °C for 1 hour. After removing the supernatant, DMEM medium containing 1.6% carboxymethylcellulose (CMC) was treated and incubated at 37 °C for 24 hours. After removing the supernatant, the cells were fixed by treatment with 4% paraformaldehyde and washed with PBS. Cell permeabilization was performed by treatment with PBS containing 0.2% Triton X-100 and 1% BSA for 30 minutes, followed by washing with PBS. After diluting the primary antibody against SARS-CoV-2 nucleocapsid (Sino Biological, China) 1:1000 in PBS containing 1% BSA, the cells were treated for 1 hour, and PBST (PBS containing 1% Tween) -20). After diluting the secondary antibody (Sino Biological, China) 1:2000 in PBS containing 1% BSA, the cells were treated for 1 hour, and washed with PBST. After treatment with KPL TrueBlue™ Peroxidase Substrate (SeraCare Life Sciences, USA), it was washed with distilled water and the number of SARS-CoV-2 foci was analyzed by Elispot reader (Cellular Technology Limited, USA). Viral infection inhibition rate was calculated using the following equation.

[Equation 1]

As a result, as shown in Table 2, when each of the peptides of SEQ ID NOs: 1 to 4 of the present invention were treated, it was confirmed that the inhibition rate of virus infection was increased in a concentration-dependent manner for all four peptides.

SEQ ID NO: Concentration (mM) Inhibition rate (%) One 2.5 21 10 100 2 2.5 51 10 96 3 2.5 98 10 98 4 2.5 55 10 98

Through this, it can be seen that the peptide of the present invention can prevent, improve and treat SARS-CoV-2 infection by inhibiting cell infection by SARS-CoV-2.

<110> CAREGEN CO., LTD. <120> Peptides able to neutralize severe acute respiratory syndrome coronavirus 2 <130> 2021-DPA-4100 <150> KR 10-2020-0088076 <151> 2020-07-16 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Peptide 1 <400> 1 Arg Ser Tyr Met Thr Thr His His Glu Gln Phe 1 5 10 <210> 2 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Peptide 2 <400> 2 Lys Phe Asn Arg Arg His His 1 5 <210> 3 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Peptide 3 <400> 3 Lys Tyr Leu Leu Val His Arg Pro Tyr Tyr Arg Arg 1 5 10 <210> 4 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Peptide 4 <400> 4 Trp Val Pro Tyr Gln Ala Arg Val Pro Tyr Pro Arg 1 5 10 <210> 5 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Peptide 5 <400> 5 Arg Leu Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg 1 5 10 <210> 6 <211> 9 <212> PRT <213> Artificial Sequence <220> <223> Peptide 6 <400> 6 Lys His Arg Gly Gly Gly Asn Arg Arg 1 5

Claims (8)

A peptide consisting of the amino acid sequence of SEQ ID NO: 1.
The method according to claim 1,
The peptide is to specifically recognize a protein or a part thereof of type 2 severe acute respiratory syndrome coronavirus (Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), a peptide.
3. The method according to claim 2,
The protein of the type 2 severe acute respiratory syndrome coronavirus is a spike protein, a peptide.
The method according to claim 1,
The peptide binds to the spike protein on the surface of the type 2 severe acute respiratory syndrome coronavirus, thereby inhibiting the binding of the spike protein to the cell membrane receptor of the host cell. delete delete delete delete

Images